key: cord-0845957-3q36jni6
authors: Kacimi, S. E. O.; Greca, E.; Haireche, M. A.; Sallam ElHawary, A.; Ould Setti, M.; Caruana, R.; Rizwan, S.; Benyettou, H.; Yasir Essar, M.; Shah, J.; Ghozy, S.
title: The Place of Fluvoxamine in the Treatment of Non-critically ill Patients with COVID-19: A Living Systematic Review and Meta-analysis
date: 2021-12-21
journal: nan
DOI: 10.1101/2021.12.19.21268044
sha: ef4517d7b7a9df2f82ffb2754ab1fd31f2e5acbb
doc_id: 845957
cord_uid: 3q36jni6

Background: Fluvoxamine is a selective serotonin reuptake inhibitor that is known to be used as antidepressant. Repurposing of Fluvoxamine for the treatment of COVID-19 is theorized to help in the prevention of the clinical deterioration of SARS CoV-2 patients. In our systematic review and meta-analysis, we aim to assess the safety and efficacy of the drug under study in terms of its effect on the mortality and the risk of hospitalization and mechanical ventilation in non-critically ill COVID-19 patients. Methods: We performed a systematic search of seven electronic databases. The search results were screened based on the previously determined inclusion and exclusion criteria. We determined the data related to our objectives. The mortality rates, rates of hospitalization, risk of mechanical ventilation and serious side effects were extracted from the studies that successfully met our inclusion and exclusion criteria. Then, the extracted data from the included studies was included in the meta-analysis. Results: Three studies, two randomized clinical trials and one observational cohort study, with 1762 patients, were the final outcome of our search and screening processes. Among all participants, 886 patients received Fluvoxamine while 876 were controls. Follow up periods ranged from 7 days to 28 days. There was no significant difference in the intention-to-treat mortality rates between the two groups (RR = 0.66; 95% CI: 0.36 - 1.21, p-value = 0.18; I2 = 0%). However, Fluvoxamine decreased the per-protocol mortality compared to both placebo alone or placebo/standard care (RR = 0.09; 95% CI: 0.01 - 0.64, p-value = 0.02; I2 = 0% and RR = 0.09; 95% CI: 0.01 - 0.72, respectively). As compared to placebo or standard care, the all-cause hospitalization was significantly reduced in the fluvoxamine group (RR = 0.71; 95% CI: 0.54 - 0.93, p-value = 0.01; I2 = 61%). This risk reduction was not significant when compared to placebo alone (RR = 0.76; 95% CI: 0.57 - 1.00; p-value = 0.051; I2 = 48%). Furthermore, the risk of mechanical ventilation was not improved in the fluvoxamine group as compared to placebo (RR = 0.71; 95% CI: 0.43 - 1.16, p-value = 0.17; I2 = 0%). The serious adverse effects were almost the same in the treatment group and the control (13% and 12% respectively). Conclusion: Fluvoxamine does not significantly reduce the mortality rates or the risk of mechanical ventilation in SARS CoV-2 patients. Nonetheless, it was found to have a good impact on reducing all cause hospitalization among patients with COVID-19 disease. Therefore, further clinical studies are needed to determine the effectiveness of the drug and its mechanisms of action.

Coronavirus disease 2019 (COVID-19) is a pandemic that has emerged in the city of Wuhan, 83 China, at the end of 2019 and has spread with highly transmissibility all over the globe in 84 2020 [1] , [2] , [3] . Symptoms severity, according to the largest cohort of more than 44,000 persons 85 infected with COVID-19 from China, can range from mild (81%), severe (14%) to critical (5%) 86

[4], [5] . During the critical phase, patients may rapidly deteriorate one week after coronavirus 87 disease onset, which increases the urge to discover drugs that prevents this condition [6] , [7] . 88

In November 2020, a randomized clinical trial, reported by Dr. Lenze and his colleagues 89 assessed the efficacy of Fluvoxamine (FLV) in adult patients with COVID-19 for prevention of 90 clinical deterioration [8] . FLV is a selective serotonin reuptake inhibitor (SSRI), mainly used to 91 treat obsessive-compulsive disorder, but also major depressive disorder and anxiety disorders [9] . 92 It has not been FDA-approved for the treatment of any infection since April 2021 when it was 93 added to the US National Institutes of Health (NIH) COVID-19 Guidelines Panel [10] . 94

Potential mechanisms of action of FLV for COVID-19 are the immune modulation aspect and 95 antiviral effect [11, 12, 13] . There are four factors that might play a key role in immune modulation. 96

First, the activity of the sigma 1 receptor that could be leading to inositol-requiring enzyme 97 1alpha -driven (IRE1). Second, the decreased activity of platelet aggregation. Third, decreased 98 activity of mast cells. Fourth, increased level of melatonin by cytochrome P450 inhibition. All of 99 them play a significant role in decreasing inflammation during COVID-19 [11, 12, 14] . On the other 100 hand, the anti-viral effect of FLV is focused on the interference with viral entry and 101 endolysosomal viral trafficking [11] . 102

Data Source 117 118 We followed the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-119 Analyses) checklist for reporting systematic reviews and meta-analyses [15] . One investigator 120 systematically searched Medline, Google Scholar, Scopus, Opengrey, Clinicaltiral.gov, 121

Cochrane, and MedRxiv from database inception till November 1 st , 2021 to retrieve studies in 122 humans of the efficacy and safety of Fluvoxamine in the treatment of non-critically ill patients 123 with confirmed COVID-19 diagnosis. The following keywords were used for the retrieval of 124 relevant studies: "Fluvoxamine", "COVID", "COVID-19", and "Coronavirus". Additionally, 125 the reference list of the included studies was scrutinized to retrieve further studies. Finally, we 126 included all original studies with no publication date or language restrictions to not miss any 127 relevant papers. 128 129

Studies were considered relevant if 1) their aim was to assess the efficacy and/or safety of 132 Fluvoxamine in the treatment of non-severe cases of COVID-19 2) they are double-arm studies 133

3) patients in these studies diagnosed with COVID-19 or its symptomatology is not severe 134 enough to require hospitalization at baseline 4) reported enough data to be used in the meta-135 analysis. Therefore, we included both observational studies (cohort studies) and clinical trials. 136

Studies conducted among ICU-admitted patients were not considered in this meta-analysis. If a 137 specific dataset has been published more than once, we used the most recent publication. 138

Preprints without peer-reviewed publication were also included. We excluded studies that were 139 not reported as full reports such as conference abstracts and letters unless they provide enough 140 data. Secondary studies including systematic reviews, narrative reviews, and computational 141 studies were excluded from this systematic review. Studies performed on animal models were 142 also excluded. The following data were extracted by two independent reviewers from each article: country, 147 study design, number of participants in both Fluvoxamine and control arms, Fluvoxamine dose, 148 and drug-intake duration, duration of the follow-up, percentage of participants lost in follow-up, 149 and description of the reported primary outcomes. Additionally, demographic data of studies' 150 participants were also extracted. Separately, the outcomes reported in the studies including 151 intention-to-treat mortality, per-protocol mortality, mechanical ventilation, hospitalization, 152 presence of serious adverse events (SAE), and presence of any adverse events (AE) were 153 extracted as raw data (event and total) and not as effect estimates. Grade 3, 4, and 5 adverse 154 events reported by the TOGETHER study [16] were considered as SAEs. The quality of the 155 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The primary endpoint was to assess the effect of Fluvoxamine on the risk of mortality, 161 mechanical ventilation, or hospitalization among COVID-19 patients without severe illness at 162 baseline. In the first part, we gathered raw data represented by the number of event occurrences 163 among total patients in each arm from both observational and interventional studies. Thereafter, 164

we calculated pooled effect estimates and their corresponding 95% confidence intervals (CI) 165 from these raw data. At the second time, only interventional studies comparing Fluvoxamine 166 with placebo were considered in separate meta-analyses. Because of the prospective nature of all 167 the included studies, Relative Risk (RR) was used as an effect estimate. 168

All data were analyzed by means of the "meta" package; R software version 4.0.2. We computed 170 the pooled RRs and their corresponding 95% CI using the fixed effects model. Heterogeneity of 171 the effect across studies was assessed by Q 2 statistics, which is distributed as X 2 statistics [18] . A 172 value of p-value < 0.05 was used to indicate a lack of homogeneity (heterogeneity) among 173 effects. I 2 statistics were provided to quantify the percentage of total variation across studies that 174 was attributable to heterogeneity rather than to chance. We used a fixed-effects model if the I 2 p-175 value significance was < 0.05. Otherwise, a random-effects model was used. Due to the small 176 number of the included studies (<10 per the analysis), neither subgroup analysis, Egger's 177 regression test for the assessment of publication bias nor meta-regression were possible [19, 20] . preclinical studies have proven their success in improving the condition of patients with these 293 two diseases [26, 27] . 294

Repurposing of fluvoxamine was theorized to be beneficial in preventing the progression of 295 severity of SARS CoV-2 disease [8] . These theories were based on the anti-inflammatory 296 properties of the drug which come mainly from its moderate to high affinity to sigma-1 receptors 297 (S1R) [28] . Among all antidepressants, fluvoxamine was found to have the highest potency at S1R 298 [29] [30] [31] . S1R is an endoplasmic reticulum (ER) chaperone protein that plays a regulatory role of 299 cytokines production in the sittings of inflammation [30] . It interferes with the ER stress (cytokine 300 storm) syndrome which occurs accordingly to the SARS CoV-2 viral replication within the 301 human cells and contributes to the high mortality of the disease [30, [32] [33] . In addition, S1R was 302 identified by Gordon et al to play a pivotal inhibitory role in the viral RNA replication process of 303 SARS CoV-2 [30, 34] . Thus, the agonistic effect of fluvoxamine on sigma-1 receptors has 304 drugs that may reduce the high risk of death especially in advanced age [35, 36] . In their large 319 multicenter retrospective observational cohort study, Oskotsky et al indicated the effectiveness of 320 SSRIs, specifically fluoxetine and fluoxetine or fluvoxamine, in reducing the mortality rates 321 among the groups that used this category of antidepressants compared to the control group [37] . In 322 our review, we found that there was no significant difference in the ITT mortality rates between 323 fluvoxamine group and placebo or SC (RR = 0.66; 95% CI: 0.36 -1.21). However, the PP 324 mortality from the TOGETHER trial indicated a real and effective difference between the two 325 groups (RR = 0.09; 95% CI: 0.01 -0.64). Therefore, this can give the preference to the use of 326 fluoxetine over fluvoxamine in the reduction of mortality among COVID-19 patients. We can 327 also infer from this the superiority of fluoxetine and fluvoxamine over the other SSRIs [37, 38] . 328 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint 

World Health Organization. Corona-virus disease (COVID-19) outbreak

Outbreak of pneumonia of unknown etiology in wuhan China: 354 the mystery and the miracle

The continuing 2019-nCoV epidemic threat of novel coronaviruses to global 356 health -the latest 2019 novel coronavirus outbreak in Wuhan

Viral dynamics in mild and severe cases of 359

COVID-19. The Lancet Infectious Diseases

Chinese Center for Disease Control and Prevention. The epidemiological 362 characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China

Clinical course and outcomes of critically ill patients with SARS-365

CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Patterns of Deterioration in Moderate Patients With COVID-19 From 368

Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric 385 diseases and its clinical implication

Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-388 1 receptor

Severe Acute Respiratory Syndrome Coronavirus Envelope Protein Regulates Cell Stress 393 Response and Apoptosis

Preferred Reporting Items for Systematic 396

The PRISMA Statement

Effect 399 of early treatment with fluvoxamine on risk of emergency care and hospitalisation among 400 patients with COVID-19: the TOGETHER randomised, platform clinical trial

Quality Assessment Tools

Cochrane Handbook for Systematic Reviews of Interventions